Geron Corporation (GERN) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Foster City, CA, 美国. 现任CEO为 Harout Semerjian.
GERN 拥有 IPO日期为 1996-07-31, 229 名全职员工, 在 NASDAQ Global Select, 市值为 $1.08B.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
